NASH
The SYNERGY Study on Tirzepatide: A Game-Changer for MASH Treatment
Metabolic dysfunction–associated steatohepatitis (MASH), formerly called nonalcoholic steatohepatitis (NASH), is a severe liver disease. MASH involves fat buildup, liver inflammation, and cell injury, often leading to fibrosis. With rising obesity and type 2 diabetes, MASH cases are growing globally.
Published
MAESTRO Study: Resmetirom’s Breakthrough in NASH Treatment and Cardiovascular Risk Reduction
Rezdiffra (Resmetirom), an oral medication targeting the liver and selective for thyroid hormone receptor β, demonstrated promising results. At doses of 80mg and 100mg, it achieved NASH resolution in 25% and 30% of participants, respectively, compared to just 10% in the placebo group.
Published
What is Insulin Resistance?
Insulin resistance is a condition in which the body’s cells become less responsive to the effects of insulin, a hormone produced by the beta cells in the pancreas. Insulin is central for regulating blood sugar (glucose) levels, facilitating the uptake of glucose by cells for energy.
Published
7 Effects of Diabetes on Liver Health
Diabetes can have significant consequences on the liver, both directly and indirectly. The liver plays a critical role in regulating blood sugar levels and metabolizing various nutrients. Here are some of the consequences of diabetes on liver health.
Published
Coffee extends longevity
This major prospective study finds that coffee consumption reduces all cause mortality by 12% in men and 7% in women. About 500,000 participants were followed for 16 years. More specifically, coffee intake seems to lower gastrointestinal death in men by 60%. In women however, the digestive, circulatory, and cerebrovascular disease mortality are reduced by 40%, 22% and 30% respectively, while raising the risk death by 30% from an ovarian cancer. The study also uncovers the antiinflammatory effect…
Published
Children, Lipodystrophy and Leptin
Lipodystrophy (LD) could be familial or acquired, partial or generalized. This original NIH study shows that metreleptin, a leptin analog, can nicely improve LD metabolic anomalies; such as high glucose, triglycerides and liver enzymes. These benefits are expected to decrease long-term lipodystrophy complications in young individuals. GT
Published
2016 Guidelines: Lipodystrophy
Lipodystrophy syndromes (LDS) are defined by severe deficiency in body fat in the absence of food restriction or starvation. They are very rare and could be classified as complete vs. partial or inherited vs. acquired. Uncontrolled LDS could affect multiple organs including heart, liver, kidney and pancreas. Diabetes, hypertriglyceridemia, and fatty liver disease are common. Diet and exercise are the cornerstone therapies. In special cases Metreleptin could also be used. GT
Published
NASH can raise risk of colorectal cancer
Non-alcoholic fatty liver disease, NAFLD or NASH is a manifestation of advanced obesity. It can lead to liver inflammation, cirrhosis and even malignancy. This association study suggests it can also increase the risk of colorectal cancer. The bigger the severity of liver disease, the higher the chance of colorectal carcinoma. A group of 26,000 asymptomatic patients were analyzed. GT
Published